Vyome (HIND) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vyome (HIND) has outperformed Lantern Pharma (LTRN) over the past year, losing 65.4% versus a loss of 81.9%. Over five years, LTRN leads with a -91.7% price change compared with -100.0% for HIND. Vyome is the larger company by market cap ($14.2 million vs $12.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIND | LTRN |
|---|---|---|
| Share price | $2.03 | $0.83 |
| Market cap | $14.25M | $12.40M |
| 1-day change | -0.49% | -8.79% |
| YTD return | -40.99% | -72.61% |
| 1-year return | -65.42% | -81.92% |
| 5-year return | -100.00% | -91.71% |
| P/E ratio (TTM) | 1.14 | — |
| EPS (TTM) | $1.78 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.56 | $4.68 |
| 52-week low | $1.75 | $0.83 |
| Distance from 52-week high | -69.05% | -82.26% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +334.98% | +2008.43% |
| Average volume | 13.32K | 180.42K |
| Shares outstanding | 7.02M | 14.94M |
| Employees | 9 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HIND has outperformed LTRN by 16.5 percentage points over the past year.
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Healthcare · Biotechnology · 9 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Healthcare · Biotechnology · 16 employees
HIND vs LTRN FAQ
Which is bigger, Vyome or Lantern Pharma?
Vyome (HIND) is larger, with a market capitalization of $14.25M compared with $12.40M for Lantern Pharma (LTRN).
Which stock has performed better over the past year, HIND or LTRN?
HIND returned -65.42% over the past 12 months, compared with -81.92% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are Vyome and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.